Samia J Khoury1, James Rochon2, Linna Ding3, Margie Byron2, Kristin Ryker4, Patti Tosta4, Wendy Gao3, Mark S Freedman5, Douglas L Arnold6, Peter H Sayre4, Dawn E Smilek4. 1. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA/Abu Haidar Neuroscience Institute, American University of Beirut, Beirut, Lebanon. 2. Rho, Inc., Chapel Hill, NC, USA. 3. Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA. 4. Immune Tolerance Network, San Francisco, CA, USA. 5. University of Ottawa, Ottawa, ON, Canada. 6. NeuroRx Research and McGill University, Montreal, QC, Canada.
Abstract
BACKGROUND: Costimulatory blockade of T lymphocytes with the CTLA4-Ig fusion protein abatacept could be an effective treatment for the immune-mediated neuroinflammatory disease relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To evaluate efficacy and safety of abatacept in RRMS. METHODS:ACCLAIM (A Cooperative Clinical Study of Abatacept in Multiple Sclerosis) was a Phase II, randomized, double-blind, placebo-controlled, multi-center trial. In all, 65 of 123 planned participants with RRMS were randomized to monthly intravenous infusions of abatacept or placebo for 24 weeks in a 2:1 ratio, switched to the opposite treatment at 28 weeks, and received their final dose of study medication at 52 weeks. Enrollment was closed early due to slow accrual. The primary endpoint was the mean number of new gadolinium-enhancing (Gd+) lesions obtained on magnetic resonance imaging (MRI) scans performed every 4 weeks. RESULTS: No statistically significant differences were observed in mean number of new Gd+ MRI lesions between the abatacept and placebo groups. No statistically significant differences were observed in other MRI and clinical parameters of RRMS disease activity. Abatacept was well tolerated. CONCLUSION: The ACCLAIM study did not demonstrate efficacy of abatacept in reducing the number of new Gd+ MRI lesions, or clinical measures of disease activity in RRMS.
RCT Entities:
BACKGROUND: Costimulatory blockade of T lymphocytes with the CTLA4-Ig fusion protein abatacept could be an effective treatment for the immune-mediated neuroinflammatory disease relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To evaluate efficacy and safety of abatacept in RRMS. METHODS: ACCLAIM (A Cooperative Clinical Study of Abatacept in Multiple Sclerosis) was a Phase II, randomized, double-blind, placebo-controlled, multi-center trial. In all, 65 of 123 planned participants with RRMS were randomized to monthly intravenous infusions of abatacept or placebo for 24 weeks in a 2:1 ratio, switched to the opposite treatment at 28 weeks, and received their final dose of study medication at 52 weeks. Enrollment was closed early due to slow accrual. The primary endpoint was the mean number of new gadolinium-enhancing (Gd+) lesions obtained on magnetic resonance imaging (MRI) scans performed every 4 weeks. RESULTS: No statistically significant differences were observed in mean number of new Gd+ MRI lesions between the abatacept and placebo groups. No statistically significant differences were observed in other MRI and clinical parameters of RRMS disease activity. Abatacept was well tolerated. CONCLUSION: The ACCLAIM study did not demonstrate efficacy of abatacept in reducing the number of new Gd+ MRI lesions, or clinical measures of disease activity in RRMS.
Entities:
Keywords:
Abatacept; autoimmune diseases; clinical trial; costimulatory and inhibitory T-cell receptors; gadolinium; intervention study; magnetic resonance imaging; multiple sclerosis; relapsing-remitting
Authors: Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini Journal: Lancet Date: 2008-07-14 Impact factor: 79.321
Authors: P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper Journal: Science Date: 1992-08-07 Impact factor: 47.728
Authors: Afsaneh Shirani; Yinshan Zhao; Mohammad Ehsanul Karim; Charity Evans; Elaine Kingwell; Mia L van der Kop; Joel Oger; Paul Gustafson; John Petkau; Helen Tremlett Journal: JAMA Date: 2012-07-18 Impact factor: 56.272
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Tihamer Orban; Craig A Beam; Ping Xu; Keith Moore; Qi Jiang; Jun Deng; Sarah Muller; Peter Gottlieb; Lisa Spain; Mark Peakman Journal: Diabetes Date: 2014-05-16 Impact factor: 9.461
Authors: Simon Glatigny; Barbara Höllbacher; Samantha J Motley; Cathy Tan; Christian Hundhausen; Jane H Buckner; Dawn Smilek; Samia J Khoury; Linna Ding; Tielin Qin; Jorge Pardo; Gerald T Nepom; Laurence A Turka; Kristina M Harris; Daniel J Campbell; Estelle Bettelli Journal: J Immunol Date: 2019-01-25 Impact factor: 5.422
Authors: Michael Osadebey; Marius Pedersen; Douglas Arnold; Katrina Wendel-Mitoraj Journal: IEEE J Transl Eng Health Med Date: 2018-08-23 Impact factor: 3.316
Authors: Ide Smets; Barnaby Fiddes; Josselyn E Garcia-Perez; Di He; Klara Mallants; Wenjia Liao; James Dooley; George Wang; Stephanie Humblet-Baron; Bénédicte Dubois; Alastair Compston; Joanne Jones; Alasdair Coles; Adrian Liston; Maria Ban; An Goris; Stephen Sawcer Journal: Brain Date: 2018-03-01 Impact factor: 13.501